ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Benztropine (benzatropine): Drug information

Benztropine (benzatropine): Drug information
(For additional information see "Benztropine (benzatropine): Patient drug information" and see "Benztropine (benzatropine): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Cogentin [DSC]
Brand Names: Canada
  • Benztropine Omega;
  • PDP-Benztropine;
  • VPI-Benztropine
Pharmacologic Category
  • Anti-Parkinson Agent, Anticholinergic;
  • Anticholinergic Agent
Dosing: Adult
Drug-induced extrapyramidal symptoms

Drug-induced extrapyramidal symptoms (eg, dystonia, parkinsonism):

Note: Diphenhydramine is not recommended for the management of akathisia (Ref).

Acute treatment: IM, IV, Oral: Note: Parenteral administration is preferred for initial treatment of severe acute symptoms. Once severe symptoms have resolved, transition to oral treatment. Duration of therapy and prophylactic use should be based on severity of extrapyramidal symptoms (EPS) reaction, pharmacologic profile of the causative agent (eg, half-life, adverse effects), and patient risk factors (Ref). Some experts recommend attempting taper and discontinuation after several weeks to months (Ref).

General dosing recommendations: Initial: IM, IV, Oral: 1 to 2 mg 2 to 3 times daily; adjust dose based on response and tolerability in 0.5 mg increments at intervals >5 days up to a maximum daily dose of 6 mg.

Dystonic reactions:

Initial dose: IM, IV, Oral: 1 to 2 mg once.

Subsequent doses: Oral: 1 to 2 mg 1 to 2 times daily.

Prevention, dystonic reactions: Note: May be useful for preventing acute dystonic reactions when administering drugs with increased risk of causing such reactions (eg, haloperidol, metoclopramide) (Ref); however, in general oral prophylactic use is not recommended to prevent antipsychotic-associated EPS (Ref).

IM, IV: 1 to 2 mg prior to administration of high-risk medication (Ref).

Parkinsonism

Parkinsonism: IM, IV, Oral:

Idiopathic parkinsonism: Initial: 0.5 to 1 mg/day as a single dose at bedtime or in 2 to 4 divided doses. Titrate in 0.5 mg increments every 5 to 6 days based on response and tolerability. Usual dose: 1 to 2 mg/day (range: 0.5 to 6 mg/day) although some patients may need 4 to 6 mg/day; maximum: 6 mg/day.

Postencephalitic parkinsonism: Initial: 2 mg/day as a single dose at bedtime or in 2 to 4 divided doses; a lower initial dose of 0.5 mg at bedtime may be considered in highly sensitive patients. Titrate in 0.5 mg increments every 5 to 6 days based on response and tolerability. Usual dose: 1 to 2 mg/day (range: 0.5 to 6 mg/day); maximum: 6 mg/day.

Note: Lower initial doses may be appropriate for older and thinner patients.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Avoid use (Ref).

Dosing: Pediatric

(For additional information see "Benztropine (benzatropine): Pediatric drug information")

Drug-induced extrapyramidal symptoms

Drug-induced extrapyramidal symptoms (EPS): Limited data available: Note: Prophylactic use is generally not recommended to prevent antipsychotic-associated EPS, especially for second-generation antipsychotics; consider individual preferences, history of EPS, and baseline risk factors for EPS, including antipsychotic receptor binding and adverse effect profile (Ref).

Children >3 years and Adolescents: Oral, IM, IV: 0.02 to 0.05 mg/kg/dose 1 to 2 times daily has been used for treatment of EPS; usual adult dose range: 1 to 4 mg/dose (Ref). The IV route should be reserved for situations when oral or IM are not appropriate. In clinical trials of pediatric patients ≥8 years with early-onset schizophrenia spectrum disorders (EOSS), benztropine 0.5 mg orally twice daily has been used to reduce the risk of development of anti-psychotic drug-induced EPS due to first-generation antipsychotics (ie, molindone) (Ref). Prophylactic benztropine is not recommended in patients treated with second-generation antipsychotics (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions (Significant): Considerations
Anticholinergic effects

Benztropine may cause anticholinergic effects, such as blurred vision, constipation, mydriasis, paralytic ileus, tachycardia, urinary retention, and xerostomia. Anticholinergic effects may require dose reduction or treatment discontinuation. (Ref)

Mechanism: Dose-related; related to the pharmacologic action. Directly related to antagonism of muscarinic receptors (Ref).

Risk factors:

• Higher doses (Ref)

• Older age (Ref)

• Concomitant use with medications with anticholinergic properties (Ref)

Hyperthermia

Benztropine can cause anhidrosis, which may result in life-threatening hyperthermia or heatstroke (Ref).

Mechanism: Dose-related; related to the pharmacologic action. Antagonism of central and peripheral muscarinic receptors results in increased heat production due to increased muscle activity and impaired sweat gland function (Ref).

Risk factors:

• Environmental heat exposure (Ref)

• Concomitant use with other anticholinergic medications (Ref)

• Existing sweating disorder

Psychiatric effects

Benztropine may cause psychiatric effects, including confusion, depression, delirium, psychotic symptoms, memory impairment, and nervousness. Psychiatric effects are reversible with discontinuation (Ref)

Mechanism: Dose-related; related to pharmacologic action. Related to antagonism of muscarinic receptors (Ref). Dopaminergic and noradrenergic activity may also contribute to effects of CNS activation (Ref).

Onset: Varied; hallucinations and psychosis have been reported as early as 45 minutes and up to several months following treatment initiation (Ref). Effects on memory and cognition have been reported within 4 days of treatment initiation (Ref).

Risk factors

• Higher doses (Ref)

• Older patients (>60 years) (Ref)

• Pediatric patients (Ref)

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Postmarketing:

Cardiovascular: Tachycardia

Endocrine & metabolic: Heatstroke (Stadnyk 1983)

Gastrointestinal: Constipation, nausea, paralytic ileus (Kwiatkowski 2011), vomiting, xerostomia

Genitourinary: Dysuria, urinary retention

Hypersensitivity: Hypersensitivity reaction

Nervous system: Depression, hyperthermia (Manivannan 2021), lethargy, nervousness, numbness of fingers, psychotic symptoms, toxic psychosis (including confusion, disorientation, memory impairment, visual hallucination) (Grace 1997)

Ophthalmic: Blurred vision, mydriasis

Miscellaneous: Fever, hyperpyrexia (Green 2001)

Contraindications

Hypersensitivity to benztropine mesylate or any component of the formulation.

Children <3 years of age (due to atropine-like adverse effects including severe anhidrosis and fatal hyperthermia) and should be used cautiously in older children.

Warnings/Precautions

Concerns related to adverse effects:

• Muscle weakness: When given in large doses or to susceptible patients, may cause weakness and inability to move particular muscle groups.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with tachycardia.

• GI obstruction: Use with caution in patients with obstructive disease of the GI tract (eg, pyloric or duodenal obstruction).

• Glaucoma: Use with caution in patients with glaucoma; avoid use in angle-closure glaucoma.

• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture or retention.

Special populations:

• Pediatric: Use with caution in children >3 years of age due to its anticholinergic effects; dose has not been established. Use is contraindicated in children <3 years of age.

Other warnings/precautions:

• Tardive dyskinesia: Not recommended for use in patients with tardive dyskinesia; benztropine does not relieve symptoms of tardive dyskinesia and may potentially exacerbate symptoms.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection, as mesylate:

Cogentin: 1 mg/mL (2 mL [DSC])

Generic: 1 mg/mL (2 mL)

Solution, Injection, as mesylate [preservative free]:

Generic: 1 mg/mL (2 mL)

Tablet, Oral, as mesylate:

Generic: 0.5 mg, 1 mg, 2 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Benztropine Mesylate Injection)

1 mg/mL (per mL): $27.00 - $37.50

Tablets (Benztropine Mesylate Oral)

0.5 mg (per each): $0.20 - $0.53

1 mg (per each): $0.23 - $0.57

2 mg (per each): $0.25 - $0.68

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection, as mesylate:

Generic: 1 mg/mL (2 mL)

Tablet, Oral, as mesylate:

Generic: 1 mg, 2 mg [DSC]

Administration: Adult

Oral: Administer with or without food.

Injectable: Administer IM or IV if oral route is unacceptable. Manufacturer’s labeling states there is no difference in onset of effect after IV or IM injection and therefore there is usually no need to use the IV route. No specific instructions on administering benztropine IV are provided in the labeling. The IV route has been reported in the literature (slow IV push when reported), although specific instructions are lacking (Ref).

Administration: Pediatric

Oral: May be given with or without food; administration with food may decrease GI upset.

Parenteral: IV route should be reserved for situations when oral or IM are not appropriate. Manufacturer's labeling states there is no difference in onset of effect after IV or IM injection and therefore there is usually no need to use the IV route. No specific instructions on administering benztropine IV are provided in the labeling. The IV route has been reported in the literature in adults (slow IV push when reported), although specific instructions are lacking (Ref).

Use: Labeled Indications

Drug-induced extrapyramidal symptoms, acute treatment: Acute treatment drug-induced extrapyramidal symptoms (excluding tardive dyskinesia).

Parkinsonism: Adjunctive therapy of all forms of parkinsonism.

Medication Safety Issues
Sound-alike/look-alike issues:

Benztropine may be confused with bromocriptine

Older Adult: High-Risk Medication:

Beers Criteria: Benztropine (oral) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its highly anticholinergic properties. It is not recommended for the prevention or treatment of extrapyramidal symptoms with antipsychotics. In the treatment of Parkinson disease, more effective agents are available (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Substrate of CYP2D6 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Risk C: Monitor therapy

Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Risk C: Monitor therapy

Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Risk C: Monitor therapy

Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. Risk C: Monitor therapy

Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination

CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider therapy modification

Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor therapy

Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). Risk X: Avoid combination

Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Ioflupane I 123: Benztropine may diminish the diagnostic effect of Ioflupane I 123. Risk C: Monitor therapy

Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Risk C: Monitor therapy

Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Risk X: Avoid combination

Lisuride: Benztropine may enhance the adverse/toxic effect of Lisuride. Risk X: Avoid combination

Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor therapy

Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor therapy

Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor therapy

Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid combination

Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid combination

Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Risk X: Avoid combination

Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. Risk X: Avoid combination

Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider therapy modification

Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination

Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Risk C: Monitor therapy

Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Pregnancy Considerations

Paralytic ileus (which resolved rapidly) was reported in two newborns exposed to a combination of benztropine and chlorpromazine during the second and third trimesters and the last 6 weeks of pregnancy, respectively (Falterman 1980).

Breastfeeding Considerations

It is not known if benztropine is excreted in breast milk. Anticholinergic agents may suppress lactation.

Monitoring Parameters

Pulse, anticholinergic effects (baseline; as clinically indicated), mental alertness.

Mechanism of Action

Possesses both anticholinergic and antihistaminic effects. In vitro anticholinergic activity approximates that of atropine; in vivo it is only about half as active as atropine. Animal data suggest its antihistaminic activity and duration of action approach that of pyrilamine maleate.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action:

IM, IV: Within a few minutes; there is no significant difference between onset of effect after intravenous or intramuscular injection

Oral: Within 1 hour

Metabolism: Hepatic (N-oxidation, N-dealkylation, and ring hydroxylation) (from animal studies only) (Brocks 1999)

Time to peak, plasma: Oral: 7 hours (Brocks 1999)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AT) Austria: Cogentin;
  • (AU) Australia: Benztrop | Cogentin;
  • (CZ) Czech Republic: Apo benztropine;
  • (DE) Germany: Cogentinol;
  • (EG) Egypt: Cogentin | Cogintol;
  • (FI) Finland: Akitan | Cogentin;
  • (GB) United Kingdom: Cogentin;
  • (HK) Hong Kong: Apo benztropine | Cogentin;
  • (IE) Ireland: Cogentin;
  • (JP) Japan: Cogentin;
  • (KR) Korea, Republic of: Benzpin | Benzpine | Benztropine | Myungin benztropine mesylate | Wi benztropine;
  • (MY) Malaysia: Apo benztropine | Cogentin;
  • (NO) Norway: Cogentin;
  • (NZ) New Zealand: Benztrop | Cogentin;
  • (PL) Poland: Cogentin;
  • (PR) Puerto Rico: Benztropine mesylate | Cogentin;
  • (PT) Portugal: Cogentin;
  • (QA) Qatar: Cogintol;
  • (SA) Saudi Arabia: Cogentin | Pms benztropine;
  • (SE) Sweden: Cogentin;
  • (SG) Singapore: Apo-Bentropine | Cogentin;
  • (TH) Thailand: Cogentin | Phatropine;
  • (TW) Taiwan: Cogentin
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Ananth JV, Jain RC. Benztropine psychosis. Can Psychiatr Assoc J. 1973;18(5):409-414. doi:10.1177/070674377301800511 [PubMed 4746144]
  3. Bellman MH. Treatment of phenothiazine drug intoxication with benztropine. Arch Dis Child.1974;49(8):664-665. [PubMed 4424791]
  4. Benztropine injection [prescribing information]. Lake Forest, IL: Akorn, Inc.; November 2017.
  5. Benztropine tablets [prescribing information]. Livonia, MI: Major Pharmaceuticals; October 2017.
  6. Benztropine Mesylate (USP tablets) [prescribing information]. Warren, NJ: Cipla USA, Inc; February 2020.
  7. Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999;2(2):39-46. [PubMed 10952768]
  8. Cogentin (benztropine) injection [prescribing information]. Lake Forest, IL: Akorn, Inc; September 2016.
  9. Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol. 2012;26(9):1167-1174. doi:10.1177/0269881112447988 [PubMed 22651987]
  10. Duncan MA, Nikolov NM, and O'Kelly B. Acute chorea due to ondansetron in an obstetric patient. Int J Obstet Anesth. 2001;10(4):309-311. [PubMed 15321589]
  11. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr. 1980;97(2):308-310. [PubMed 740090]
  12. Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010;49(6):583-594 [PubMed 20494268]
  13. Gelenberg AJ, Van Putten T, Lavori PW, et al. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol. 1989;9(3):180-185. [PubMed 2661606]
  14. Grace RF. Benztropine abuse and overdose--case report and review. Adverse Drug React Toxicol Rev. 1997;16(2):103-112. [PubMed 9359932]
  15. Green H, Gilbert J, James R, Byard RW. An analysis of factors contributing to a series of deaths caused by exposure to high environmental temperatures. Am J Forensic Med Pathol. 2001;22(2):196-199. doi:10.1097/00000433-200106000-00018 [PubMed 11394759]
  16. Habre W, Wilson D, Johnson CM. Extrapyramidal side-effects from droperidol mixed with morphine for patient-controlled analgesia in two children. Paediatr Anaesth. 1999;9(4):362-364. [PubMed 10411778]
  17. Hitri A, Craft RB, Fallon J, Sethi R, Sinha D. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacol Bull. 1987;23(1):33-37. [PubMed 2885890]
  18. Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 1997;54(21):2461-2477. [PubMed 9359953]
  19. Joseph MM, King WD. Dystonic reaction following recommended use of a cold syrup. Ann Emerg Med. 1995;26(6):749-751. [PubMed 7492048]
  20. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-41. doi: 10.1056/NEJM199601043340109. [PubMed 7494570]
  21. Kao RL, Kelly LM. Fatal exertional heat stroke in a patient receiving zuclopenthixol, quetiapine and benztropine. Can J Clin Pharmacol. 2007;14(3):e322-e325. [PubMed 18025545]
  22. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901 [PubMed 32867516]
  23. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103. doi: 10.1093/schbul/sbp130. [PubMed 19955388]
  24. Kwiatkowski M, Denka ZD, White CC. Paralytic ileus requiring hospitalization secondary to high-dose antipsychotic polypharmacy and benztropine. Gen Hosp Psychiatry. 2011;33(2):200.e5-200.e7. doi:10.1016/j.genhosppsych.2010.10.005 [PubMed 21596217]
  25. Lydon AM and Boylan JF. Reversibility of parkinsonism-induced acute upper airway obstruction by benztropine therapy. Anesth Analg. 1998;87(4):975-976. [PubMed 9768805]
  26. Manivannan A, Kabbani D, Levine D. Use of multiple anticholinergic medications can predispose patients to severe non-exertional hyperthermia. BMJ Case Rep. 2021;14(3):e239873. doi:10.1136/bcr-2020-239873 [PubMed 33758045]
  27. McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2007;46(8):969-978. [PubMed 17667476]
  28. McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008 [PubMed 23972700]
  29. McEvoy JP. A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry. 1987;48 Suppl:20-23. [PubMed 2887553]
  30. McEvoy JP, “The Clinical Use of Anticholinergic Drugs as Treatment for Extrapyramidal Side Effects of Neuroleptic Drugs,” J Clin Psychopharmacol, 1983, 3(5):288-302. [PubMed 6138370]
  31. Moreau A, Jones BD, Banno V. Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia. Can J Psychiatry. 1986;31(4):339-41. doi:10.1177/070674378603100411 [PubMed 3708528]
  32. Musselman ME, Saely S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health Syst Pharm. 2013;70(1):34-42. doi:10.2146/ajhp110543 [PubMed 23261898]
  33. Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.
  34. Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68(1):37-49. doi:10.1111/pcn.12088 [PubMed 24102938]
  35. Pagliaro A, Mattio B, Paulson N, Fromm C, Vidal J. Unprovoked dystonic reaction in a child taking long-term methylphenidate. J Pharm Pract. 2022;35(5):796-799. doi:10.1177/0897190021999781 [PubMed 33813918]
  36. pdp-Benztropine (benztropine) [prescribing information]. Montréal, Québec, Canada: Pendopharm; June 2020.
  37. Sachdev P and Loneragan C. Intravenous benztropine and propranolol challenges in tardive akathisia. Psychopharmacology (Berl). 1993;113 (1):119-122. [PubMed 7862817]
  38. Schramm BM and Orser BA. Dystonic reaction to propofol attenuated by benztropine (Cogentin). Anesth Analg. 2002;94(5):1237-1240. [PubMed 11973196]
  39. Stadnyk AN, Glezos JD. Drug-induced heat stroke. Can Med Assoc J. 1983;128(8):957-959. [PubMed 6831343]
  40. Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 28, 2022.
  41. Syndulko K, Gilden ER, Hansch EC, Potvin AR, Tourtellotte WW, Potvin JH. Decreased verbal memory associated with anticholinergic treatment in Parkinson's disease patients. Int J Neurosci. 1981;14(1-2):61-66. doi:10.3109/00207458108985816 [PubMed 7263143]
  42. Teoh L, Allen H, Kowalenko N. Drug-induced extrapyramidal reactions. J Paediatr Child Health. 2002;38(1):95-97. [PubMed 11869410]
  43. Thornton SL, Farnaes L, Minns A. Prolonged antimuscarinic delirium in a child due to benztropine exposure treated with multiple doses of physostigmine. Pediatr Emerg Care. 2016;32(4):243-245. doi:10.1097/PEC.0000000000000503 [PubMed 26383155]
  44. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy. 1994;14(5):543-560. [PubMed 7997388]
  45. Wilcox JA. Psychoactive properties of benztropine and trihexyphenidyl. J Psychoactive Drugs. 1983;15(4):319-321. doi:10.1080/02791072.1983.10471970 [PubMed 6655530]
Topic 9106 Version 476.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟